Status:
RECRUITING
Tegoprazan-Based Dual Therapy With Amoxicillin vs Tetracycline for H. Pylori Eradication
Lead Sponsor:
Zhongshan Hospital (Xiamen), Fudan University
Conditions:
Helicobacter Pylori Eradication
High-dose Dual Therapy
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Current first-line Helicobacter pylori eradication protocols involve multidrug regimens comprising a proton pump inhibitor (PPI) or bismuth agent combined with dual antibiotics (e.g., clarithromycin, ...
Detailed Description
Helicobacter pylori (H. pylori) infection remains a significant global health burden, strongly associated with peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lympho...
Eligibility Criteria
Inclusion
- Age from 18 to 65 years;
- H.pylori infection diagnosed by 13C-urea breath test;
- The patient infected with Helicobacter pylori has never undergone eradication therapy.
Exclusion
- Allergy to any of the medications;
- Zollinger-Ellison syndrome, GC, Upper gastrointestinal bleeding, or Active peptic ulcer;
- Coexistence of significant concomitant illnesses, including heart disease, renal failure, hepatic disease, previous abdominal surgery, lactation, or pregnancy;
- Patients who had used PPI/P-CAB drugs, and antibiotics in the past 12 weeks;
- Unwillingness to participate in this study.
Key Trial Info
Start Date :
June 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2026
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT06977841
Start Date
June 10 2025
End Date
May 30 2026
Last Update
August 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital (Xiamen), Fudan University
Xiamen, Fujian, China, 361015